Recent evidence showing that activation of the innate immune system is a viable anti-cancer therapeutic approach prompted us to test the hypothesis that treatment of PDA-bearing mice with murine STING agonist, DMXAA, would induce tumor regression. The gene discussed is STING1; the disease is Patent ductus arteriosus.